+

WO2013011061A1 - Anticorps anti-oscar - Google Patents

Anticorps anti-oscar Download PDF

Info

Publication number
WO2013011061A1
WO2013011061A1 PCT/EP2012/064108 EP2012064108W WO2013011061A1 WO 2013011061 A1 WO2013011061 A1 WO 2013011061A1 EP 2012064108 W EP2012064108 W EP 2012064108W WO 2013011061 A1 WO2013011061 A1 WO 2013011061A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
oscar
seq
binding
cells
Prior art date
Application number
PCT/EP2012/064108
Other languages
English (en)
Inventor
Li Guo
Svetlana PANINA
Jesper Pass
Louise Hjerrild ZEUTHEN
Louise Maymann NITZE
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of WO2013011061A1 publication Critical patent/WO2013011061A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to compounds useful in treatment and prophylaxis of diseases such as autoimmune inflammatory diseases and bone resorption related disorders.
  • the present invention furthermore relates to OSCAR antagonists as well as use of such compounds.
  • Osteoclast-associated receptor is an activating receptor expressed on osteoclasts and myeloid-derived cells, including monocytes, macrophages, neutrophils and dendritic cells. It was reported that OSCAR is up-regulated in the synovial tissue as well as in circulating CD14 + cells from rheumatoid arthritis patients. Triggering of OSCAR signalling leads to secretion of pro-inflammatory cytokines and chemokines from monocytes and dendritic cells, promotes differentiation of osteoclasts and hence may be causally involved in the pathogenesis of the inflammation-induced bone resorption. Collagens type I, II, III, and IV have been shown to act as ligands for OSCAR (WO2010040998).
  • the present invention thus relates to OSCAR antagonists, preferably OSCAR antibodies, as well as use of such compounds in treatment of various diseases such as e.g. autoimmune inflammatory diseases.
  • OSCAR antagonists preferably OSCAR antibodies
  • Such antagonists have the ability to reduce
  • the present invention furthermore relates to methods for inducing collagen dependent maturation of monocyte-derived Dendritic Cells.
  • the present invention relates to OSCAR antagonists that are useful in connection with treatment of patients suffering from autoimmune inflammatory diseases such as e.g. rheumatoid arthritis.
  • the compounds of the invention may also be used in treatment of other disorders associated with bone resorption.
  • FIG. 1 Anti-OSCAR mAb 13F5A5 inhibit osteoclast formation from normal monocytes
  • OSCAR the osteoclast-associated receptor
  • LRC leukocyte receptor complex
  • OSCAR protein (further referred as "OSCAR", encoded by mRNA with Genebank accession number AF391 162), is a single-span trans-membrane protein comprising 263 amino acids residues (SEQ ID NO 1 ). It associates with FcRy which serves as a signalling subunit of the receptor complex. Sequences of six additional putative OSCAR isoforms can be found in various databases (Uniprot accession number Q81 YS5-1 , Q81 YS5-2, Q81 YS5-3, Q81YS5- 4, Q81YS5-5, Q81YS5-6, Q81YS5-7). All isoforms seem to be resulting from the alternative splicing of a common RNA precursor. Some isoforms are predicted to lack a transmembrane domain due to a frame shift mutation and thus encode for putative secreted proteins.
  • OSCAR- ECD extracellular domain of OSCAR
  • OSCAR- ECD extracellular domain of OSCAR
  • SEQ ID NO 2 The amino acid sequence of human OSCAR-S1 a is shown in SEQ ID NO 3.
  • SEQ ID NO 4 The amino acid sequence of human OSCAR-S1 b is shown in SEQ ID NO 4.
  • OSCAR variants refer to proteins having OSCAR activity but comprise one or more alterations in comparison with wt OSCAR, such as e.g. one or more amino acid substitutions/deletions/additions.
  • SEQ ID NO 1 Human OSCAR (putative signal peptide marked with bold)
  • SEQ ID NO 2 Human OSCAR-ECD
  • SEQ ID NO 4 Human OSCAR-S1 b
  • WO2010040998 discloses that collagen proteins/peptides can act as ligands for OSCAR. WO2010040998 furthermore discloses that OSCAR binding to collagen peptides stimulates the activation and/or differentiation of OC. The effect can be blocked by the 1 1 .1 CN5 antibody.
  • the 1 1 .1 CN5 antibody is an anti-human OSCAR mAb and it is an R- phycoerythrin conjugated antibody provided in a composition comprising sodium azide (https://www.beckmancoulter.com/wsrportal/search/Anti-OSCAR- PE/#2/10//0/25/1/0/asc/2/Anti-OSCAR-PE///0/1//0/).
  • Binding of antibodies and ligands to OSCAR can be measured by ELISA and SPR using recombinant proteins or by FACS and FMAT using transfected cells or cells naturally expressing OSCAR, such as e.g. monocytes.
  • OSCAR activation upon ligand binding can be assessed by e.g. analysing expression of cell surface markers using FACS, by detecting cytokine release using ELISA or Bio-Plex; by detecting a reporter gene activity or by using an osteoclast formation assay.
  • Collagen is the main component of connective tissue and extracellular matrix and are the most abundant protein in mammals. Collagen type I is mainly found in skin, tendon, vascular, ligature and bone (major protein component of bone). Collagen type II is mainly found in cartilage (major protein component of cartilage). Collagen type III is mainly found in reticulate (major component of reticular fibres). Collagen types I, II, III, and IV are the "fibrillar collagens”. Collagen I may herein be referred to as "Coll”, collagen II as "Colli, collagen III as “Collll” and collagen IV as "CollV”.
  • the compounds according to the invention can be used in the treatment of diseases involving an inappropriate or undesired immune response (immunological disorders), such as inflammation, autoimmunity, and conditions involving such mechanisms as well as graft vs. host disease.
  • diseases involving an inappropriate or undesired immune response such as inflammation, autoimmunity, and conditions involving such mechanisms as well as graft vs. host disease.
  • disease or disorder is an autoimmune and/or inflammatory disease.
  • autoimmune and/or inflammatory diseases are systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) (including ulcerative colitis (UC) and Crohn's disease (CD)), multiple sclerosis (MS), scleroderma, type 1 diabetes (T1 D), pemphigus vulgaris (PV), psoriasis, atopic dermatitis, celiac disease, Hashimoto's thyroiditis, Graves' disease, Sjogren's syndrome, Guillain-Barre syndrome, Goodpasture's syndrome, Addison's disease, Wegener's granulomatosis, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, polymyalgia rheumatica, Raynaud's syndrome, temporal arteritis, giant cell arteritis, autoimmune hemolytic anemia, pernicious anemia
  • RA Rheumatoid arthritis
  • RA is a systemic autoimmune disease that affects the entire body and is one of the most common forms of arthritis. It is characterized by the inflammation of the synovial membrane lining a joint, which causes pain, stiffness, warmth, redness and swelling. Inflammatory cells release enzymes that may digest bone and cartilage. As a result of RA, the inflamed joint lining, the synovium, can invade and damage bone and cartilage leading to joint deterioration and severe pain amongst other physiologic effects. The involved joint can lose its shape and alignment, resulting in pain and loss of movement.
  • Anti-inflammatory biological therapeutics are now available for the treatment of rheumatoid arthritis (e.g. anti-CD20, a TNF-R antagonist or anti-TNF-a). However, none of these medicaments are specifically reducing bone erosion in RA patients.
  • mice develop chronic inflammatory arthritis that closely resembles human RA.
  • CIA collagen-induced arthritis
  • treatment refers to the medical therapy of any human subject or other animal subject in need thereof. Said subject is expected to have undergone physical examination by a medical or veterinary medical practitioner, who has given a tentative or definitive diagnosis which would indicate that the use of said specific treatment is beneficial to the health of said human or other animal subject.
  • the timing and purpose of said treatment may vary from one individual to another, according to the status of the subject's health.
  • said treatment may be prophylactic, palliative, symptomatic and/or curative.
  • prophylactic, palliative, symptomatic and/or curative treatments may represent separate aspects of the invention.
  • antibody herein refers to a protein, derived from a germline
  • immunoglobulin sequence capable of specifically binding to an antigen or a portion thereof.
  • the term includes full length antibodies of any isotype (i.e. IgA, IgD, IgE, IgG, IgM and/or IgY), any antigen binding fragment thereof, and any chain thereof. Examples of various types of molecules being encompassed by the definition of "antibodies” are listed below. Antibodies may be referred to in various ways herein, e.g. "antibody”, “Ab”, “mAb”, “monoclonal antibody”, etc, and such terms may be used interchangeably.
  • Full-length antibodies usually comprise at least four polypeptide chains: that is, two heavy (H) chains and two light (L) chains that are interconnected by disulfide bonds.
  • One immunoglobulin sub-class of particular pharmaceutical interest is the IgG family, which may be sub-divided into isotypes lgG1 , lgG2, lgG3 and lgG4.
  • IgG molecules are composed of two heavy chains, usually interlinked by two or more disulfide bonds, and two light chains, ordinarily attached to a heavy chain by a disulfide bond.
  • a heavy chain may comprise a heavy chain variable region (VH) and up to three heavy chain constant (CH) regions: CH1 , CH2 and CH3.
  • a light chain may comprise a light chain variable region (VL) and a light chain constant region (CL).
  • VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • VH and VL regions are typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy- terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
  • the hypervariable regions of the heavy and light chains form a binding domain that is capable of interacting with an antigen, whilst the constant region of an antibody may mediate binding of the immunoglobulin to host tissues or factors, including but not limited to various cells of the immune system (effector cells), Fc receptors and the first component (Clq) of the classical complement system.
  • antigen-binding fragments include Fab, Fab', F(ab)2, F(ab')2, F(ab)S, Fv (typically the VL and VH domains of a single arm of an antibody), single-chain Fv (scFv; see e.g.. Bird et al., Science 1988; 242:42S-426; and Huston et al.
  • dsFv, Fd typically the VH and CHI domain
  • dAb typically a VH domain
  • VH, VL, VhH, and V-NAR domains monovalent molecules comprising a single VH and a single VL chain
  • minibodies, diabodies, triabodies, tetrabodies, and kappa bodies see, e.g., Ill et al.
  • antigen-binding fragment refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding fragment" of an antibody include a Fab fragment, a F(ab') 2 fragment, a Fab' fragment, a Fd fragment, a Fv fragment, a ScFv fragment, a dAb fragment and an isolated complementarity determining region (CDR).
  • CDR complementarity determining region
  • Single chain antibodies such as scFv and heavy chain antibodies such as VHH and camel antibodies are also encompassed within the term "antigen-binding portion" of an antibody.
  • antibody fragments may be obtained using conventional techniques known to those of skill in the art, and the fragments may be screened for utility in the same manner as intact antibodies.
  • Fab fragments including “Fab” and “Fab(ab') 2 " fragments, of an antibody are derived from said antibody by cleavage of the heavy chain in the hinge region on the N- terminal or C-terminal side of the hinge cysteine residues connecting the heavy chains of the antibody.
  • a “Fab” fragment includes the variable and constant domains of the light chain and the variable domain and the first constant domain (CH1 ) of the heavy chain.
  • F(ab') 2 " fragments comprise a pair of "Fab” fragments that are generally covalently linked by their hinge cysteines.
  • a Fab' is usually derived from a F(ab') 2 fragment by cleavage of the hinge disulfide bonds connecting the heavy chains in the F(ab') 2 .
  • a Fab fragment retains the ability of the parent antibody to bind to its antigen.
  • F(ab') 2 fragments are capable of divalent binding, whereas Fab and Fab' fragments can bind monovalently.
  • Fab fragments lack the constant CH2 and CH3 domains, i.e. the Fc part, where interaction with the Fc receptors would occur.
  • Fab fragments are in general devoid of effector functions.
  • Fab fragments may be produced by methods known in the art, either by enzymatic cleavage of an antibody, e.g. using papain to obtain the Fab or pepsin to obtain the F(ab') 2 , or Fab fragments may be produced recombinantly using techniques that are well known to the person skilled in the art.
  • an "Fv” fragment is an antibody fragment that contains an antigen recognition and binding site, and generally comprises a dimer of one heavy chain variable domain and one light chain variable domain.
  • the association between the heavy chain variable domain and the light chain variable domain can be covalent in nature, for example in a single chain variable domain fragment (scFv). It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site/paratope on the surface of the VH-VL dimer.
  • scFv single chain variable domain fragment
  • variable domain comprising only three hypervariable regions specific for an antigen has the ability to recognize and bind antigen, although usually at a lower affinity than the entire binding site (Cai & Garen, Proc. Natl. Acad. Sci. USA, 93: 6280-6285, 1996).
  • VHH heavy chain variable domain
  • Single-chain Fv or “scFv” antibody fragments comprise the VH and VL domains, where these domains are present in a single polypeptide chain.
  • the Fv Single-chain Fv or “scFv” antibody fragments
  • polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.
  • a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments with two antigen-binding sites, in which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH and VL) by way of a linker.
  • VH heavy chain variable domain
  • VL light chain variable domain
  • VH and VL polypeptide chain
  • linker that is too short to allow pairing between the two variable domains on the same chain, the variable domains are forced to pair with complementary domains of another chain, creating two antigen-binding sites.
  • Diabodies are described more fully, for example, in EP 404,097; WO 93/1 1 161 ; and Hollinger et al., 1993, Proc. Natl. Acad. Sci. USA, 90:6444- 6448.
  • linear antibodies refers to antibodies as described in Zapata et al., 1995, Protein Eng., 8(10):1057-1062. Briefly, these antibodies contain a pair of tandem Fd segments (VH-CH1 -VH-CH1 ) that, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
  • a monobody can bind to an antigen in the absence of light chains and typically has three hypervariable regions, for example CDRs designated CDRH1 , CDRH2, and CDRH3.
  • An IgG monobody has two heavy chain antigen binding molecules connected by a disulfide bond.
  • the heavy chain variable domain comprises one or more hypervariable regions, preferably a CDRH3 or HVL-H3 region.
  • Antibody fragments may be obtained using conventional recombinant or protein engineering techniques. Antibody fragments of the invention may be made by truncation, e.g. by removal of one or more amino acid residues from the N and/or C-terminal ends of a polypeptide. Fragments may also be generated by one or more internal deletions.
  • An antibody of the invention may be a human antibody or a humanized antibody.
  • human antibody is intended to include antibodies having variable regions in which at least a portion of a framework region and/or at least a portion of a CDR region are derived from human germline immunoglobulin sequences.
  • a human antibody may have variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences.
  • the constant region is also derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences ⁇ e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • Such a human antibody may be a human monoclonal antibody.
  • Such a human monoclonal antibody may be produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.
  • Human antibodies may be isolated from sequence libraries built on selections of human germline sequences, further diversified with natural and synthetic sequence diversity. Human antibodies may be prepared by in vitro immunisation of human lymphocytes followed by transformation of the lymphocytes with Epstein-Barr virus.
  • human antibody derivative refers to any modified form of the human antibody, such as a conjugate of the antibody.
  • humanized antibody refers to a human/non-human chimeric antibody that contains a sequence (CDR regions) derived from a non-human immunoglobulin.
  • a humanized antibody is, thus, a human immunoglobulin (recipient antibody) in which at least one or more residues from a hyper-variable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) for example from a mouse, rat, rabbit, or non-human primate, which have a desired property, such as specificity, affinity, and capacity.
  • donor antibody for example from a mouse, rat, rabbit, or non-human primate
  • FR residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • An example of such a modification is the introduction of one or more so-called back-mutations.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • a humanized antibody will comprise at least one - typically two - variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and in which all or substantially all of the FR residues are those of a human immunoglobulin sequence.
  • the humanized antibody can, optionally, also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • humanized antibody derivative refers to any modified form of the humanized antibody, such as a conjugate of the antibody and another agent or antibody.
  • chimeric antibody refers to an antibody whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes that originate from different species.
  • variable segments of genes from a mouse monoclonal antibody may be joined to human constant segments.
  • the fragment crystallizable region (“Fc region Fc domain”) of an antibody is the C-terminal region of an antibody, which comprises the constant CH2 and CH3 domains.
  • the Fc domain may interact with cell surface receptors called Fc receptors, as well as some proteins of the complement system.
  • the Fc region enables antibodies to interact with the immune system.
  • antibodies may be engineered to include modifications within the Fc region, typically to alter one or more of its functional properties (i.e. Fc effector functions), such as serum half-life, complement fixation, Fc-receptor binding, protein stability and/or antigen-dependent cellular cytotoxicity, or lack thereof, among others.
  • an antibody of the invention may be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or may be modified to alter its
  • a modified Fc domain comprises one or more, and perhaps all of the following mutations that will result in decreased affinity to certain Fc receptors (L234A, L235E, and G237A) and in reduced C1 q-mediated complement fixation (A330S and P331 S), respectively (residue numbering according to the EU index).
  • Antibodies having this type of Fc domain are sometimes referred to as "non-depleting" antibodies.
  • Antibodies without an Fc domain tend to have a relatively short in vivo circulatory half life.
  • half life extending moieties include: Biocompatible fatty acids and derivatives thereof, Hydroxy Alkyl Starch (HAS) e.g.
  • HES Hydroxy Ethyl Starch
  • PEG Poly Ethylen Glycol
  • HAP Poly (Glyx- Sery)n
  • HAP Hyaluronic acid
  • HEP Heparosan polymers
  • PC polymer Phosphorylcholine-based polymers
  • Fleximers Dextran
  • Poly-sialic acids PSA
  • Fc domain Fc domain
  • the isotype of an antibody of the invention may be IgG, such as lgG1 , such as lgG2, such as lgG4.
  • the class of an antibody may be "switched" by known techniques.
  • an antibody that was originally produced as an IgM molecule may be class switched to an IgG antibody.
  • Class switching techniques also may be used to convert one IgG subclass to another, for example: from lgG1 to lgG2 or lgG4; from lgG2 to lgG1 or lgG4; or from lgG4 to lgG1 or lgG2.
  • Engineering of antibodies to generate constant region chimeric molecules, by combination of regions from different IgG subclasses, can also be performed.
  • the hinge region of CH1 is modified such that the number of cysteine residues in the hinge region is altered, e.g., increased or decreased.
  • the constant region may further be modified to stabilize the antibody, e.g., to reduce the risk of a bivalent antibody separating into two monovalent VH-VL fragments.
  • residue S241 may be mutated to a proline (P) residue to allow complete disulphide bridge formation at the hinge (see, e.g., Angal et al., Mol Immunol. 199S; 30:105-8).
  • Antibodies or fragments thereof may also be defined in terms of their complementarity determining regions (CDRs).
  • CDRs complementarity determining region
  • the CDRs are generally comprised of amino acid residues 24-34 (L1 ), 50-56 (L2) and 89-97 (L3) in the light-chain variable domain and 31 -35 (H1 ), 50-65 (H2) and 95-102 (H3) in the heavy-chain variable domain; (Kabat et al. (1991 ) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.
  • anigen refers to the molecular entity used for immunization of an immunocompetent vertebrate to produce the antibody (Ab) that recognizes the Ag.
  • Ag is termed more broadly and is generally intended to include target molecules that are specifically recognized by the Ab, thus including fragments or mimics of the molecule used in the immunization process, or other process, e.g. phage display, used for generating the Ab.
  • epitope is defined in the context of a molecular interaction between an "antigen binding polypeptide”, such as an antibody (Ab), and its corresponding antigen (Ag).
  • an “antigen binding polypeptide” such as an antibody (Ab)
  • Ag antigen
  • epitopope refers to the area or region on an Ag to which an Ab specifically binds, i.e. the area or region in physical contact with the Ab.
  • a protein epitope may comprise amino acid residues in the Ag that are directly involved in binding to a Ab (also called the immunodominant component of the epitope) and other amino acid residues, which are not directly involved in binding, such as amino acid residues of the Ag which are effectively blocked by the Ab, i.e. amino acid residues within the "solvent-excluded surface" and/or the "footprint" of the Ab.
  • the epitope for a given Ab/Ag pair can be described and characterized at different levels of detail using a variety of experimental and computational epitope mapping methods.
  • the experimental methods include mutagenesis, X-ray crystallography, Nuclear Magnetic Resonance (NMR) spectroscopy, Hydrogen deuterium exchange Mass Spectrometry (HX- MS) and various competition binding methods as well as other methods that are known in the art.
  • NMR Nuclear Magnetic Resonance
  • HX- MS Hydrogen deuterium exchange Mass Spectrometry
  • the description of an epitope is intimately linked to the method by which it has been determined.
  • the epitope for a given Ab/Ag pair may be described differently.
  • the epitope for the interaction between the Ag and the Ab can be described by the spatial coordinates defining the atomic contacts present in the Ag-Ab interaction, as well as information about their relative contributions to the binding
  • the epitope can be characterized by the spatial coordinates defining the atomic contacts between the Ag and Ab.
  • the epitope can be characterized by the amino acid residues that it comprises as defined by a specific criteria such as the distance between or solvent accessibility of atoms in the Ab-Ag complex.
  • the epitope can be characterized through function, e.g. by competition binding with other Abs.
  • the epitope can also be defined more generically as comprising amino acid residues for which substitution by another amino acid will alter the characteristics of the interaction between the Ab and Ag.
  • Epitopes described at the amino acid level are said to be identical if they contain the same set of amino acid residues. Epitopes are said to overlap if at least one amino acid is shared by the epitopes. Epitopes are said to be separate (unique) if no amino acid residue is shared by the epitopes.
  • paratope is derived from the above definition of “epitope” by reversing the perspective.
  • the term “paratope” refers to the area or region on the Ab to which an Ag specifically binds, i.e. with which it makes physical contact to the Ag.
  • a paratope may be defined by using the definition for epitope and applying it to the antibody as opposed to the antigen.
  • Antibodies that bind to the same antigen can be characterised with respect to their ability to bind to their common antigen simultaneously and may be subjected to "competition binding / binning .
  • the term “binning” refers to a method of grouping antibodies that bind to the same antigen. “Binning” of antibodies may be based on competition binding of two antibodies to their common antigen in assays based on standard techniques such as surface plasmon resonance (SPR), ELISA or flow cytometry.
  • a "bin” can be viewed as an epitope defined using a reference antibody. If a second antibody is unable to bind to the antigen at the same time as the reference antibody, the second antibody is said to belong to the same "bin” as the reference antibody. In this case the reference and the second antibody are competing for binding to the antigen, thus the pair of antibodies is termed "competing antibodies”. If a second antibody is capable of binding to the antigen at the same time as the reference antibody, the second antibody is said to belong to a separate "bin”. In this case the reference and the second antibody are not competing for binding to the antigen, thus the pair of antibodies is termed "non-competing antibodies”. Antibody "binning" does not provide direct information about the epitope. Competing antibodies, i.e.
  • antibodies belonging to the same "bin” may have identical epitopes, overlapping epitopes or even separate epitopes. The latter is the case if the reference antibody bound to its epitope on the antigen takes up the space required for the second antibody to contact its epitope on the antigen ("steric hindrance").
  • Non-competing antibodies generally have separate epitopes.
  • “competing with collagen for binding to OSCAR” means the ability of an antibody, or a fragment thereof, to reduce in a dose dependent manner, the binding of collagen or fragments thereof, to OSCAR.
  • a method to measure this can be, but is not limited to, surface plasmon resonance (SPR) analysis performed on a biosensor instrument, e.g. Biacore instruments as described in example 13 (50 nM OSCAR is used as an analyte and mixed with 0-10 ⁇ g ml prior to injection into e.g. a Biocore T 100 instrument (GE healthcare) Human collagen I and collagen II are immobilized on e.g. a Biacore CM3 sensor chip (GE
  • OSCAR Antibodies according to the invention having the ability to significantly reduce OSCAR:collagen binding are those that can reduce OSCAR:collagen binding by at least 15%, preferably at least 20%, preferably at least 25%, preferably at least 30%, preferably at least 35%, preferably at least 40%, preferably at least 45%, preferably at least 50%, preferably at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95% compared to e.g. a control antibody.
  • Reduction of collagen induced cytokine secretion means the ability of an antibody, or a fragment thereof, to reduce in a dose dependent manner collagen induced cytokine secretion.
  • Collagen such as collagen I
  • Collagen may furthermore induce maturation of dendritic cells (DCs).
  • Reduction of collagen induced cytokine secretion can e.g. be measured in the following way: Collagen I and collagen II are immobilized on a surface of essentially neutral charge (e.g. Costar #3361 ).
  • RA synovial fluid cells e.g.
  • OSCAR antibodies according to the invention having the ability to reduce collagen induced cytokine secretion/DC cell maturation are those that can reduce cytokine secretion/DC cell maturation by at least 20%, preferably at least 25%, preferably at least 30%, preferably at least 35%, preferably at least 40%, preferably at least 45%, preferably at least 50%, preferably at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95% compared to e.g. a control antibody.
  • Reduction of TRAP positive (TRAP + ) osteoclast formation means the ability of an antibody, or a fragment thereof, to reduce in a dose dependent manner TRAP + osteoclast formation.
  • OSCAR antibodies according to the present invention may have the ability to reduce TRAP + cell numbers in normal monocytes - and thereby reducing osteoclast formation.
  • Reduction of TRAP + osteoclast formation can e.g. be detected using the following assay: 60,000 monocytes/well are cultured with recombinant human M-CSF (25 ng/ml) and soluble RANKL (100 ng/ml). The cells are cultured on uncoated plastic. After ended incubation (day 9-12), the cells are stained for TRAP, e.g. using a leukocyte acid
  • OSCAR antibodies according to the present invention may thus reduce TRAP + 5 cell numbers in normal monocytes by at least 20%, preferably at least 25%, preferably at least 30%, preferably at least 35%, preferably at least 40%, preferably at least 45%, preferably at least 50%, preferably at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%.
  • Reduction of TRAP5b secretion by osteoclasts means the ability of an antibody, or a fragment thereof, to reduce in a dose dependent manner TRAP5b secretion by osteoclasts.
  • OSCAR antibodies according to the present invention may have the ability to reduce
  • TRAP5b secretion by osteoclasts wherein said osteoclasts are derived from normal monocytes.
  • Reduction of TRAP5b secretion by osteoclasts can e.g. be detected using the following assay: 60,000 monocytes/well are cultured with recombinant human M-CSF (25 ng/ml) and soluble RANKL (100 ng/ml). The cells are cultured on uncoated plastic. After ended incubation (day 9-12), the supernatants from cell cultures are collected for ELISA measurements of TRAP5b.
  • OSCAR antibodies according to the present invention may thus reduce TRAP5b secretion by osteoclasts derived from normal monocytes by at least 20%, preferably at least 25%, preferably at least 30%, preferably at least 35%, preferably at least 40%, preferably at least 45%, preferably at least 50%, preferably at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%.
  • Reduction of bone resorption from osteologic discs and/or bone slices means the ability of an antibody, or a fragment thereof, to reduce in a dose dependent manner bone resorption from osteologic discs and/or bone slices.
  • Reduction of bone resorption can e.g. be detected using the following assay: 60,000 monocytes/well are cultured with recombinant human M-CSF (25 ng/ml) and soluble RANKL (100 ng/ml). The cells are cultured on osteologic dies or bone slices. After ended incubation (day 9-12), bone resorption can be detected in one or more of the following way: (i) image analysis of erosion on osteologic discs /bone slides by e.g.
  • OSCAR antibodies according to the present invention may reduce bone resorption from osteologic discs and/or bone by at least 20%, preferably at least 25%, preferably at least 30%, preferably at least 35%, preferably at least 40%, preferably at least 45%, preferably at least 50%, preferably at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%.
  • Jmmunoreacts or “immunoreacting”, as used herein, means any binding of an antibody to its epitope with a dissociation constant K d lower than 10 "4 M.
  • the terms “immunoreacts” or “immunoreacting” are used where appropriate inter-changeably with the term “specifically bind”.
  • affinity means the strength of the binding of an antibody to an epitope.
  • the affinity of an antibody is measured by the dissociation constant K d , defined as [Ab] x [Ag] / [Ab-Ag] where [Ab-Ag] is the molar concentration of the antibody- antigen complex, [Ab] is the molar concentration of the unbound antibody and [Ag] is the molar concentration of the unbound antigen.
  • K d dissociation constant
  • an "antagonist” is a compound that does not provoke a biological response upon binding to a receptor or a ligand, but blocks or dampens agonist-mediated responses.
  • an "agonist” is a compound that induces a response upon binding to a receptor or ligand.
  • an antagonist Upon binding to a target, an antagonist will reduce the cell response induced by an agonist, such as e.g. a natural ligand or a compound that functionally resembles the effects of the natural ligand.
  • OSCAR induced effects may refer to at least one of an inflammatory response or differentiation of OC.
  • An inflammatory response can include but is not limited to activation of a cell of the immune system (e.g., T and B lymphocytes; polymorphonuclear leukocytes or granulocytes, such as neutrophils; monocytes, dendritic cells, macrophages, and NK cells), recruitment of a cell of the immune system, or release of a cell-derived soluble pro-inflammatory mediator, such as for example a cytokine or chemokine.
  • a cell of the immune system e.g., T and B lymphocytes; polymorphonuclear leukocytes or granulocytes, such as neutrophils; monocytes, dendritic cells, macrophages, and NK cells
  • a cell-derived soluble pro-inflammatory mediator such as for example a cytokine or chemokine.
  • Differentiation of OC can include, but is not limited to, expression of cellular markers for OC differentiation by monocytes-derived precursors or bone marrow precursors, increased cell fusion, increased tartrate-resistant acid phosphatase (TRAP) activity, increased cathepsin K expression, increased beta 3 integrin expression, multinucleation, and bone resorption.
  • cellular markers for OC differentiation by monocytes-derived precursors or bone marrow precursors
  • increased cell fusion increased tartrate-resistant acid phosphatase (TRAP) activity
  • TRIP tartrate-resistant acid phosphatase
  • a ligand can be said to antagonize OSCAR induced effects, for example, if it mediates at least about 20% inhibition, preferably at least about 30% inhibition, more preferably at least about 40% inhibition, more preferably at least about 50% inhibition, and most preferably at least about 75% inhibition of IL-8 release from dendritic cells (DCc) induced by Coll (example 8) at antibody concentrations below 10 nM.
  • DCc dendritic cells
  • a “receptor” is a protein molecule, embedded in either the plasma membrane (e.g. a transmembrane protein) or present in the cytoplasm of a cell, to which one or more specific signaling molecules may attach.
  • a molecule which specifically binds (attaches) to a receptor is called a "ligand", and may be an antibody, a peptide or other small molecule, such as a neurotransmitter, a hormone, a pharmaceutical drug, or a toxin.
  • Ligand binding generally stabilizes a certain receptor conformation. This is often associated with gain of or loss of receptor activity, often leading to a cellular response. However, some ligands (e.g.
  • Monoclonal antibodies are typically made by fusing myeloma cells with the spleen cells from a mouse that has been immunized with the desired antigen.
  • Human antibodies can be obtained from transgenic animals (e.g. mice) encoding human antibodies.
  • recombinant monoclonal antibodies can be made and identified involving technologies, referred to as repertoire cloning or phage display/yeast display. Recombinant antibody identification involves the use of viruses or yeast to display antibodies for selection, rather than the use of e.g. mice.
  • Antibodies may be produced by means of recombinant techniques.
  • the DNA sequences encoding the antibody are usually inserted into a recombinant vector.
  • the vector is preferably an expression vector in which the DNA sequence is operably linked to a promoter capable of directing the transcription of a cloned antibody gene or antibody cDNA in the desired host cell.
  • the host cell may be any cell, which is capable of producing the antibody and includes bacteria, yeast, other fungi and higher eucaryotic cells.
  • Examples of mammalian cell lines for use in the present invention are COS- 1 , baby hamster kidney (BHK) and HEK293.
  • a preferred BHK cell line is the tk- ts13 BHK cell line that may be referred to as BHK 570 cells.
  • a number of other cell lines, or their derivatives may be used within the present invention, including Rat Hep I, Rat Hep II, TCMK, NCTC 1469, CHO, and DUKX cells.
  • the transformed or transfected host cell described above is then cultured in a suitable nutrient medium under conditions permitting expression of the antibody.
  • the antibody may be subsequently recovered from the culture by conventional procedures including separating the host cells from the medium by centrifugation or filtration,
  • precipitating the proteinaceous components of the supernatant or its filtrate for example, by means of a salt, e.g. ammonium sulphate
  • purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gelfiltration chromatography, affinity chromatography, or the like, dependent on the type of polypeptide in question.
  • Transgenic animal technology may be employed to produce the antibody of the invention. It is preferred to produce the antibodies in the mammary glands of a host female mammal, preferably in sheeps, goats or cattle. Production in transgenic plants may also be employed. Expression may be directed to a particular organ, such as a tuber.
  • the present invention further includes pharmaceutical compositions/formulations comprising antibodies according to the invention and optionally comprising a
  • compositions according to the invention may be in the form of an aqueous formulation or a dried formulation that is reconstituted in water/an aqueous buffer prior to administration.
  • Pharmaceutical compositions comprising compounds according to the invention may be supplied as a kit comprising a container that comprises the products according to the invention.
  • Therapeutic polypeptides can be provided in the form of an injectable solution for single or multiple doses, or as a sterile powder that will be reconstituted before injection.
  • Pharmaceutical compositions comprising compounds according to the invention are suitable for subcutaneous and/or IV administration.
  • An antibody that binds to human OSCAR and antagonizes OSCAR induced effects wherein said antibody competes with antibody 7F1A1 for binding to OSCAR, wherein the amino acid sequence of the 7F1 A1 heavy chain is as set forth in SEQ ID NO 6 and the amino acid sequence of the 7F1 A1 light chain is as set forth in SEQ ID NO 5.
  • epitope or at least a portion of the same epitope, as the 7F1 A1 antibody.
  • An antibody that binds to human OSCAR and antagonizes OSCAR induced effects wherein said antibody competes with antibody 7F21A1 for binding to OSCAR, wherein the amino acid sequence of the 7F21 A1 heavy chain is as set forth in SEQ ID NO 16 and the amino acid sequence of the 7F21A1 light chain is as set forth in SEQ ID NO 15.
  • epitope or at least a portion of the same epitope, as the 7F21A1 antibody.
  • An antibody that binds to human OSCAR and antagonizes OSCAR induced effects wherein said antibody competes with antibody 3F7A9 for binding to OSCAR, wherein the amino acid sequence of the 3F7A9 antibody heavy chain is as set forth in SEQ ID NO 20 and the amino acid sequence of the 3F7A9 light chain is as set forth in SEQ ID NO 19.
  • An antibody according to the invention, wherein said antibody is not an R- phycoerythrin conjugated antibody.
  • An antibody according to the invention, wherein said antibody is not an 1 1.1 CN5 antibody.
  • an antibody comprising the three CDR sequences as set forth in SEQ ID NO 6 and three CDR sequences as set forth in SEQ ID NO 5.
  • said antibody comprises at least one CDR (e.g. CDR3) from SEQ ID NO 6 and at least one CDR (e.g. CDR3) from SEQ ID NO 5.
  • One or two amino acid alternations may be introduced in one, two, three, four, five or six of said CDR sequences.
  • said antibody comprises the entire VHA L sequences of SEQ ID NO 5 and SEQ ID NO 6.
  • An antibody comprising the three CDR sequences as set forth in SEQ ID NO 16 and the three CDR sequences as set forth in SEQ ID NO 15.
  • said antibody comprises at least one CDR (e.g. CDR3) from SEQ ID NO 16 and at least one CDR (e.g. CDR3) from SEQ ID NO 15.
  • CDR e.g. CDR3
  • CDR e.g. CDR3
  • One or two amino acid alternations may be introduced in one, two, three, four, five or six of said CDR sequences.
  • said antibody comprises the entire VHA L sequences of SEQ ID NO 15 and SEQ ID NO 16.
  • An antibody comprising the three CDR sequences as set forth in SEQ ID NO 19 and the three CDR sequences as set forth in SEQ ID NO 20.
  • said antibody comprises at least one CDR (e.g. CDR3) from SEQ ID NO 19 and at least one CDR (e.g.
  • said antibody comprises the entire VHA/L sequences of SEQ ID NO 19 and SEQ ID NO 20.
  • An antibody according to the invention wherein said antibody reduces collagen I and/or collagen II induced secretion of TNF-a and/or IL-8 in immature dendritic cells (DC).
  • An antibody according to the invention wherein said antibody reduces collagen I induced secretion of IL-8 and/or TNF-alpha from synovial fluid mononuclear cells from rheumatoid arthritis (RA) patients.
  • a pharmaceutical composition comprising an antibody according to the invention.
  • An expression vector comprising a DNA molecule according to the invention.
  • a host cell comprising an expression vector according to the invention and/or a DNA molecule according to the invention.
  • a method for making an antibody according to the invention wherein said method comprises incubating a host cell according to the invention under conditions appropriate for expression of said antibody and optionally subsequently isolating said antibody.
  • a method of treatment comprising administering to a person in need thereof an appropriate amount of an antibody according to the invention for treatment of an autoimmune inflammatory disease, such as e.g. RA.
  • a method of treatment comprising administering to a person in need thereof an appropriate amount of an antibody according to the invention for treatment of a bone resorption related disorder, such as e.g. osteoarthritis, osteoporosis, psoriatic arthritis.
  • a bone resorption related disorder such as e.g. osteoarthritis, osteoporosis, psoriatic arthritis.
  • a method for inducing collagen dependent maturation of moDCs wherein said method comprises incubating moDCs on a virgin polystyrene surface in the presence of collagen.
  • a method for inducing collagen dependent maturation of moDCs according to the invention wherein collagen is selected from the group consisting of collagen I, collagen II, and collagen III.
  • Fully human mAbs were generated by immunization of transgenic mice (HuMab mice developed by Medarex Inc.) with OSCAR-ECD (SEQ ID NO 2).
  • the HuMab mice have disabled murine IgG loci, and inserted loci encoding human IgG.
  • mice were immunized subcutaneously. For the first immunization, 2C ⁇ g of antigen was mixed with complete Freunds adjuvant. In subsequent immunizations incomplete Freund's adjuvant was used with the same amount of antigen.
  • eye-blood from the mice was analyzed by ELISA for OSCAR specific antibodies. Mice with positive titers were boosted intravenously with 1 C ⁇ g antigen in PBS, and sacrificed after 3 days. The spleens were aseptically removed and dispersed into a single cell suspension. Fusion of spleen cells and myeloma cells was performed using either the PEG-method or
  • Hybridomas secreting specific antibodies were selected using specific binding assays as described below.
  • Immunoplates (Maxisorb, Nunc) were coated with 2 ⁇ g ml OSCAR-ECD. Hybridoma culture supernatants were added to the plates. Detection was carried out with a HRP-conjugated polyclonal antibody (pAb) specific to murine or human antibodies.
  • pAb polyclonal antibody
  • OSCAR binding of antibodies to OSCAR was first examined in HEK293 cells transfected to express extracellular OSCAR. By using transfected cells it was possible to counter-screen for un- specific binding to the parental mock-transfected HEK293 cell line. The screening for OSCAR specific antibodies was done in sera, culture supernatants and in purified mAbs. Antibodies which selectively bound to the HEK-OSCAR cells were further tested for binding to primary monocytes from human PBMC expressing endogenous OSCAR.
  • OSCAR Full length human OSCAR (hOSCAR) cDNA (GenBank #AF391 162) was cloned into the Nhe ⁇ -BamY ⁇ sites of the mammalian expression vector plRESneo2 (Clontech, #6938-1 ) and used for transfection of HEK293 cells. Transfected clones were selected for drug resistance (Geneticin, Invitrogen #10131 -035). Expression of OSCAR was analysed by immunoblotting using anti-hOSCAR pAb (R&D, #AF2004).
  • OSCAR-PE phytoerythrin
  • HEK-hOSCAR clone 2-2D9 with the highest expression of OSCAR was selected for screening of anti-OSCAR mAbs.
  • the geneticin-resistant pool of HEK293 cells transfected with plRESneo2 (mock-transfectants) served as negative control.
  • PBMC peripheral blood mononuclear cells isolated by density gradient centrifugation were recovered from the interphase and thoroughly washed several times in RPMI1640 medium, spun and re-suspended either in a washing buffer (1 x PBS (-Ca 2 7-Mg 2+ ) + 1 % BSA ) for immediate use or in a cryo-medium (RPMI1640 supplemented with 20% FBS and 10% DMSO) for cryopreservation. Both freshly isolated and freeze-thawed cells were equally suitable for immunostaining followed by FACS analysis.
  • Cell number and viability were determined using a Cedex cell counter.
  • the cells were diluted in washing buffer (1 x PBS (-Ca 2 7-Mg 2+ ) + 5% FBS + 0.1 % Na-azide) to 10 7 cells/90 l.
  • the cells were further blocked by adding 10 ⁇ of a hFcR blocker (Miltenyi, # 130-059-901 ) and incubated for 10 minutes at 4°C. 50 ⁇ of cells (50.000cells/well) were seeded into 96 well round-bottomed microtiter plates. Hybridoma supernatants or purified antibodies (in serial dilutions) were added to the cells at 50 ⁇ l/well.
  • the isotype-matched purified irrelevant human mAb or mouse mAb served as negative controls (mouse lgG1 , BD, #553452; mouse lgG2a, BD, #557353; mouse lgG2b, BD, #557352).
  • the cells were incubated in the dark for 60 minutes at 4°C, washed twice and stained with the secondary antibodies (goat anti-human IgG -PE, Jackson ImmunoResearch, #109-1 16-170 or donkey anti-mouse IgG-APC (allophycocyanin), Jackson ImmunoResearch, #715-136-150), diluted 1 :500, for 30 minutes in the dark at 4°C.
  • Affinities of the anti-OSCAR mAbs towards OSCAR-ECD were measured by SPR using a Biacore T100 instrument (GE Healthcare). These studies were performed using either a direct binding procedure, with the respective mAb covalently coupled via free amine groups to the carboxy methylated dextrane membrane (CM5) on the sensor chip surface, or a capture method where the individual mAbs were captured on immobilized anti-mouse or anti-human pAbs prior to injection of OSACAR-ECD.
  • OSCAR-ECD was injected in various concentrations, followed by a dissociation period with constant buffer flow over the sensor chip surface. The kinetic parameters (k a , k d and K D ) for the interaction were calculated using a 1 :1 interaction Langmuir fitting model.
  • the measured affinities were all in the nM range and comparable to that of the mAb 1 1 .1 CN5 which was shown to interfere with the OSCAR-Coll interaction.
  • the affinity of OSCAR-ECD to Coll has been determined as 255nM by SPR analysis.
  • the sub- ⁇ affinity of this interaction is within the range of the affinities reported for Coll interaction with other members of the LRC family, including LAIR-1/-2 and GPVI.
  • the affinities of the mAbs to OSCAR are approximately 20-360 folds higher than the affinity of the OSCAR-ECD/Coll complex formation. Results are shown in Table 2.
  • the cDNAs of the light and heavy chains were cloned by RT-PCR using total RNA extracted from 10 7 cells of each anti-hOSCAR hybridomas 4F3B, 7F1A, 7F6A, 7F9A, 7F10A, 7F14A, 7F21A, and 3F7A9. Reverse transcription was performed using oligo-dT primer.
  • Antibody cDNAs were amplified using specific primers. The amplified products were cloned into the pMD19-T vector (Takara, China) and sequenced. The cDNAs were then sub-cloned into a vector for expression in mammalian cells. The recombinant antibody were produced in HEK2936E cells and purified. Amino acid sequences of the selected mAbs are listed below.
  • TTVTVSS 13F56 variable light chain and variable heavy chain sequences CDR sequences shown in bold/underline and VL VH sequences are shown in capital letters):
  • Immobilization was performed according to the standard procedure, but at 4°C in order to prevent aggregation of Coll, with immobilized levels of ca 150 RU on flow cell (FC) 2 and ca 300 RU on FC 4. A blank immobilization was performed on FC 1 & 3, which were used as reference cells.
  • HBS-EP buffer (10mM HEPES, 150mM NaCI, 3mM EDTA, 0.005% Polysorbat P20, pH7.4) was used as running buffer for the immobilization.
  • Buffer containing HBS-EP/+0.1 % BSA was used for the competition assay.
  • the competition experiment was performed at 4 °C at a flow rate of 50 ⁇ / ⁇ .
  • the OSCAR- ECD and OSCAR-S1 a proteins (SEQ ID NO 2 and SEQ ID NO 3, respectively) were used as analytes at a concentration of 50nM.
  • OSCAR was mixed with various concentrations of anti- OSCAR antibodies ranging from 0 - 5 ⁇ g ml prior to injection. Binding curves were measured for 240 s followed by 200 s of dissociation.
  • the chip surface was regenerated for 2 x 20 s with 10mM glycine, pH 2.0 between assays. All assays were performed in duplicates. Results
  • OSCAR-ECD SEQ ID NO 2
  • OSCAR-S1 a SEQ ID NO 3
  • ECD soluble extracellular domain
  • Antibody binding competition assays were performed by SPR analysis in order to investigate whether the anti-OSCAR mAbs bound simultaneously to OSCAR-ECD (SEQ ID NO 2) or cell-surface OSCAR on human PBMC.
  • SEQ ID NO 2 OSCAR-ECD
  • An inability of mAbs to bind simultaneously indicates common or overlapping epitopes, though factors such as steric hindrance and
  • Antibodies demonstrating an inhibitory effect on Coil-dependent dendritic cell maturation were represented in four bins/competitive groups (Table 4). This data demonstrates that interference with at least four distinct regions in OSCAR will influence the binding and/or activation by Coll.
  • the ligand competing data (described in Example 13) differentiate the mAbs between the four bins. Table 4: Binning of mAbs based on simultaneous binding to OSCAR
  • the aim of the binning study was to group the antibodies into competitive groups/bins according to their ability to inhibit binding of a fluorochrome labelled anti-OSCAR antibody to human monocytes. Inhibition of binding indicates that the two antibodies tested show steric hindrance of simultaneous binding to the target cells and hence belonging to the same bin. An inhibition of binding can be due to binding to the same epitope, binding to overlapping epitopes or binding to two non-overlapping epitopes albeit with steric hindrance of simultaneous binding.
  • mAbs For the quality control and facilitating gating of relevant cell populations, the following mAbs have been used: 7AAD (BD, #51 -68981 E), anti-CD3-FITC (BD, # 345763), anti-CD19-FITC (BD, # 345776) and anti-CD14-FITC (BD, #345784).
  • PBMC from healthy individuals were purified as described in Example 1 .
  • the cells were re- suspended in washing buffer (1 x PBS (-Ca 2 7-Mg 2+ ) + 1 % BSA). Viability and cell numbers were calculated using a Cedex cell counter. 10 7 cells (90 ⁇ ) were treated with 10 ⁇ hFcR blocker (Miltenyi, #130-059-901 ). The cells were incubated 10 minutes at 4°C, followed by a dilution in washing buffer to 10 6 cells/ml. Labelled antibodies were diluted in washing buffer to 2 ⁇ g ml and added as 25 ⁇ / ⁇ in a round bottom 96-well plategiving a final concentration of 0,5ug/ml og labelled antibody.
  • the mAbs could be grouped into four main groups listed in Table 5. This main grouping is based exclusively on the full inhibition profile. Although it was not possible to label the 6F3A, this mAb has been groped together with 6F6B and 7F6A1. The partial inhibition profile is less clear. Both mAbs in a test were added simultaneously, there should be no preference for one of the antibodies compared to the other. Presumably, labelling of the antibodies with AlexaFlour 647 might have an effect on binding properties. There might be a change in affinity due to labelling of the antibody, or the flexibility of the F(ab) arms may be affected by the labelling.
  • a preliminary epitope prediction of the anti-OSCAR mAb 4F3B was done using a peptide walking technique.
  • a peptide array was synthesised based on SEQ ID NO 2 with C to A mutations for all cysteins.
  • a 20- (20mer), 16- and 12 amino acid residue peptide walk was used in the design of the peptide array.
  • the frame walking was set to 2 residues.
  • the array was screened using the fluorescein-labelled mAb 4F3B.
  • the epitope mapping arrays were synthesized on cellulose sheets (Aims-Scientific) using an array synthesizer (Multipep Spot, Intavis) according to the manufacturers protocol.
  • Fmoc- amino acids (Novabiochem) were dissolved in N-methylpyrrolidinone (NMP) containing 0.3M hydrobenzotriazole (HOBt) to a final concentration of 0.3M.
  • NMP N-methylpyrrolidinone
  • HOBt hydrobenzotriazole
  • Coupling was done by activating with diisopropylcarbodiimide (DIC).
  • DIC diisopropylcarbodiimide
  • De-protection of the Fmoc group was done by 20% piperidine in NMP.
  • the individual sequences were designed using the array synthesiser software.
  • the protecting groups were removed by treatment of the sheets with 95% trifluoroacetic acid (TFA) containing triisopropylsilane (TIPS) for 60 min.
  • TIPS triisopropylsilane
  • the sheets were washed with dichloromethane (DCM) and N-methylpyrrolidinone (NMP) and finally with water.
  • the stock of the 4F3B mAb was subjected to gel-filteration chromatography, using a NAP5 column (GE Healthcare) to replace the buffer with 1 % NaHC0 3 according to the
  • the array analysis revealed that the mAb 4F3B binds to the regions corresponding to amino acid residues 29-48 and 129-146.
  • KIR2DL2 as a template, a homology model of OSCAR-ECD was built. According to the model, the binding regions for mAb 4F3B are located in each of the Ig-like domains.
  • HX-MS hydrogen exchange and mass spectrometry
  • mAbs or fractions thereof e.g. Fab fragments
  • An OSCAR variant having a Cys-to-Ala mutation in position 83 has been produced.
  • This C83A OSCAR variant can potentially be useful for protein structure determination (e.g. X-ray analysis), protein-ligand interface determination and epitope mapping.
  • Human PBMC were isolated as described in Example 1 .
  • Monocytes were purified from PBMC using MACS CD14 + beads (Miltenyi MicroBeads, #130-050-201 ). The monocytes were seeded at a cell density of 2X10 6 cells/ml and cultured for 3 days in the presence of 12.5 ng/ml IL-4 (R&D Systems, #204-IL-010) and 25 ng/ml GM-CSF (eBioscience, #14-8339) at 2x10 6 cells/ml for 3 days. The monocytes differentiated into immature DC, which were non-adherent cells of irregular shape that expressed high levels of DC-SIGN.
  • the immature DC were pre-incubated for 1 h with anti-OSCAR or control antibodies and subsequently seeded into plates (IWAKI, #1820-024) coated with Coll (Sigma, #C5483) or FCS (control) and incubated overnight.
  • the maturation state of the DC i.e. expression of HLA-DR, CD83, CD86 and DC-SIGN
  • the maturation state of the DC was assessed by flow cytometry. Secretion of cytokines was analysed by ELISA (R&D systems). TNF-a and IL8 were identified as the cytokines providing the best window (Coll versus FCS treated DCs) and thus were chosen as readouts in the screen. All mAbs and Coll used in the assay were endotoxin-free.
  • DC plated onto FCS-coated plates were used to control for agonistic properties of mAbs.
  • Anti-OSCAR mAb inhibit DC maturation and hence their ability to promote T-cell proliferation in an allogenic mixed lymphocyte reaction.
  • MLR allogenic mixed lymphocyte reaction
  • CD14+ monocytes were purified from buffy coats of healthy donors. The cells were enriched using RosetteSep Human Monocyte Enrichment Cocktail (StemCell Technology, #15068) according to the manufacturers protocol. Residual erythrocytes were lysed using RBC lysis buffer (eBioscience, # 00-4333-57) for 10 min at room temperature. Monocytes were washed twice with the buffer containing PBS, 2% FBS and 10mM EDTA, collected by centrifugation and re-suspended at the concentration of 6.7x10 5 cells/ml in the DC differentiation medium containing RPMI1640 with 2mM L-glutamine (GlutamaxTM, Gibco, # 61870), 10% FBS,
  • GM-CSF 50ng/ml human recombinant GM-CSF (R&D, #215-GM) and 50ng/ml human recombinant IL- 4 (PeproTech, #200-04).
  • 1 ,2x10 7 cells were seeded onto a 92x17 mm tissue culture plate (Nunc, # 150350) and cultured for five days in 5% C0 2 at 37°C. The medium was renewed after two days of culturing.
  • non-adherent immature DC iDC
  • iDC non-adherent immature DC
  • the cells were pre-incubated for 30 min with anti-OSCAR mAbs prior to transfer to 24 well microplates (IWAKI, #1820-024), which were coated for 3 hours at room temperature with 300 ⁇ / ⁇ of ⁇ g/ml human Coll (Sigma, #C5483) and rinsed thoroughly with PBS, or to the uncoated wells. Unless indicated, 4x10 5 cells per well were used.
  • the DC growth/survival factors 50ng/ml GM-CSF and 50ng/ml IL-4) or inducers of maturation ⁇ g/ml LPS, Sigma, #SC-3535 ) were added to the control wells.
  • the cells were cultured for two days in 5% C0 2 humidified cell incubator at 37°C.
  • Non-adherent cells were collected, extensively washed and resuspended in RPMI1640 supplemented with 10% FBS and 2mM L-glutamine (further referred as "T-cell growth medium") for further use in MLR.
  • T-cell growth medium 10% FBS and 2mM L-glutamine
  • Expression of cell surface markers was analysed by flow cytometry (see FACS analysis). Detection of cytokines in the conditioned medium was performed using Bio-Plex multiplex analysis (see Analysis of Cytokine secretion).
  • CD4 + human T-cells were isolated from buffy coats of healthy donors using RosetteSep Human CD4 + T cell Enrichment Cocktail (StemCell Technologies, #15062) according to the manufacturers protocol followed by Histopaque density gradient purification (Sigma, #10771 ). The CD4 + cells were recovered from the interphase, thoroughly washed with PBS/2% FCS and re-suspended in T-cell growth medium. The purity of the T-cells was analysed by flow cytometry (see FACS analysis).
  • DC were mixed with allogenic CD4 + T-cells in a ratio 1 :100 (10 3 DC:10 5 T- cells per well of a 96-well plate).
  • the cells were cultured in 5% C0 2 humidified cell incubator at 37°C for 5 days. T-cells cultured without DC served as negative control. At day 4 conditioned medium was collected for analysis of cytokine secretion (see Analysis of cytokine secretion).
  • the cells were then pulse-labelled with ⁇ . ⁇ / ⁇ 3 H-Thymidine (Perkin Elmer, 14.4 Ci/mmol) for 18 hours.
  • the cells were collected using a Tomtec cell harvester and lysed in distilled water. Incorporated thymidine was captured on glass fibre filters. The filters were air-dried for 20 hours at room temperature prior to quantification using a
  • cytokine secretion was assessed using a Bio-Plex system for multiple cytokine analysis (BioRad). 50 ⁇ of cell culture supernatants were analysed. Secreton of IL23(p19/p40) was analysed by ELISA (eBiosciences, #88-7239) with the capture anti-IL12p40 and detection anti-p19 Ab according to the manufacturers protocol. Data analysis was performed using the Graph Pad Prism 5.0 software.
  • Non-adherent immature DC (iDC) differentiated from monocytes in the presence of GM- CSF/IL4 were transferred either onto the plates coated with Coll and maintained in the full growth medium, or onto uncoated plates in the presence of LPS (positive control, "classical” mature DC) or uncoated plates in the presence of GM-CSF/IL4 (negative control, to maintain the iDC phenotype).
  • LPS positive control, "classical” mature DC
  • GM-CSF/IL4 negative control, to maintain the iDC phenotype
  • the Coil- induced cytokine release was inhibited by anti-OSCAR mAbs 4F3B and 3F7A9.
  • the non- inhibitory anti-OSCAR mAb 9F1 1 A2 served as an isotype control (Table 7).
  • Coll-matured DC stimulated T-cell proliferation and cytokine secretion in an allogenic MLR assay, which can be inhibited by anti-OSCAR mAbs (Table 8 and 9) .
  • Coll-matured DC stimulated T-cell proliferation at least as efficient as the classical LPS-matured DC.
  • the proliferation of T-cells was significantly lower when the cells were co- cultured with DC treated with the anti-OSCAR mAbs 4F3B and 3F7A9 (Table 8).
  • the cytokine secretion profile of the T-cells is shown in Table 9. Even though the DC used in MLR were not PFA-fixed, the T-cell growth medium does not support survival of DC, thus the contribution of the DC-derived cytokines is minimal (if any).
  • Anti-OSCAR mAbs reduce viability of DC propagated on Col
  • iDC were differentiated from CD14 + monocytes as described in Example 9. After five days, non-adherent iDC were collected and extesively washed to remove traces of GM-CSF and IL4. The cells were re-suspended at 2.5x10 6 cells/ml in the growth medium containing RPMI 1640 with GlutamaxTM, (Gibco, #61870) supplemented with 10% FBS. Prior to seeding, aliquots of 5 ⁇ 10 5 /200 ⁇ cells were pre-incubated for 30min at 37°C with 300 ⁇ of anti-OSCAR mAbs (diluted with growth medium) or with 300 ⁇ of growth medium without mAb as untreated control.
  • the cells were transferred to 24 well microplates (IWAKI, #1820-024), which were coated for 3 hours at room temperature with either 300 ⁇ / ⁇ of 10 ⁇ g ml human Coll (Sigma, #C5483) or 20 ⁇ g ml fibronectin (Sigma, #F0895) and rinsed thoroughly with PBS, or to the uncoated wells. 500 ⁇ of the growth medium was added per well. As positive control, 50ng/ml GM-CSF was added to the indicated wells. The cells were propagated for three days in a 5% C0 2 humidified cell incubator at 37°C.
  • Metabolic activity was analysed as a surrogate marker of cell viability using Alamar Blue dye (Invitrogen, # Dal1025) according to the manufacturers protocol. Fluorescence was measured at excitation 544nm/emission 590nm using a NovoStar fluorescence plate reader (BMG). Data analysis was performed using the GraphPad Prism 5.0 software.
  • Coll-OSCAR interaction promotes the survival of DCs under the conditions of grow factor withdrawal and the effect can be suppressed by anti-OSCAR mAbs.
  • Table 10 Coll-OSCAR interaction supports survival of DC under conditions of growth factor withdrawal
  • Anti-OSCAR mAbs inhibit Coll/Col ll-induced cytokine release from RA synovial fluid cells
  • RA synovial fluid from knee joints of RA patients was collected by needle aspiration at Peking University People's Hospital Hospital (Beijing, China).
  • the RA synovial fluid cells were collected by centrifugation, re-suspended in RPMI1640 medium and purified by Ficoll density gradient centrifugation.
  • RA synovial fluid mononuclear cells (RA SFMCs) were recovered from the interphase, washed twice with PBS and re-suspended in RPMI1640 supplemented with 10% FBS and 2mM L-glutamine. Analysis of Coll-induced cytokine secretion
  • OSCAR ligand Coll (Millipore, #cc050), Colli (Millipore, #cc052) , or the control protein collagen V (Millipore, #cc077), were immobilized on a 96-well plate (Costar, #3361 ) at 100 ⁇ l/well of 10Mg/ml protein solution in PBS for 4h at 37°C.
  • RA synovial fluid cells (3 ⁇ 10 5 /200 ⁇ per well) or RA SFMCs (1 x10 5 /200 ⁇ per well) were pre-incubated with the anti-OSCAR mAbs or isotype control mAbs for 1 h prior to be transferred onto the collagen-coated plate. After 24 hours incubation, the cell culture supernatants were analysed by ELISA for the presence of TNF-a, IL-6 and IL-8. Results
  • Anti-OSCAR mAbs inhibit Coll/Colll-induced inflammatory cytokine release from RA synovial fluid cells, suggesting blocking OSCAR can inhibit the induction of inflammatory responses in myeloid cells present in RA synovial fluids.
  • RA SFMCs RA synovial fluid mononuclear cells
  • Table 12 Anti-OSCAR mAbs inhibit Coil-induced TNFa secretion from RA SFMCs
  • RA SFMCs RA synovial fluid mononuclear cells
  • Osteoclast formation assays can be used to detect if an OSCAR mAb has the ability to reduce bone erosion.
  • Osteoclasts are multinucleated cells derived from myeloid progenitors that are capable of eroding bone.
  • a standard protocol for generating osteoclasts in vitro is to culture monocytes for 7-14 days in the presence of exogenous recombinant M-CSF and soluble RANKL, both factors are required and sufficient for OC formation. During such culture conditions monocytes typically change characteristics as follows:
  • PBMCs Primary human monocytes are purified by a positive selection method using anti-CD14 mAb coated microbeads. Briefly, PBMCs are isolated from buffy coats using Ficoll density gradient centrifugation. Thereafter, monocytes are isolated using CD14 microbeads followed by MACS column separation (Miltenyi Biotec, #130-050-201 ) according to the manufacturers recommendations.
  • the OC formation assay is set up in 96 well plate formats.
  • the OC formation assay is set up in a 96 well plate format. A starting concentration of 60 000 monocytes/well is used. The cells are cultured either on uncoated plastic in a final volume of 200 ⁇ of the growth medium alone (IMDM, 2% human serum, 10% FCS, P/S, 2mM L- glutamine), or in the growth medium supplemented with recombinant human M-CSF
  • each mAb is added at 10 ⁇ g ml at the initiation of culture.
  • the mAbs with hlgG1.1 backbone used in this assay are non-depleting antibodies.
  • Anti-OSCAR mAb i.e.13F5A5-hlgG1.1 ) inhibited Osteoclast formation from normal monocytes, suggesting blocking of OSCAR will reduce osteoclastogenesis and bone erosion in RA.
  • mAbs 16F1 19, 16F56, 13F56A6, 13F5A5, 16F18, 4F3B and 6F6B inhibited binding of OSCAR to collagen with very little binding left in the presence of 10Mg/ml antibody.
  • 7F10A1 , 7F14A1 , 3F7A9, 7F21A1 , 7F1A1 and the prior art antibody 1 1.1 CN5 did not interfere with binding since a concentration-dependent increase of the signal was detected.
  • Anti-OSCAR mAbs in epitope Bin#1 and #4, but not Bin #2 (incl. 1 1.1 CN5) or #3 compete the binding of Collagens to OSCAR.
  • the ligand competing data functionally differentiate the mAbs between the four epitope Bins.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps antagonistes dirigés contre OSCAR. L'invention concerne également l'utilisation de tels anticorps.
PCT/EP2012/064108 2011-07-18 2012-07-18 Anticorps anti-oscar WO2013011061A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/001173 2011-07-18
CN2011001173 2011-07-18
US201161524800P 2011-08-18 2011-08-18
US61/524,800 2011-08-18
CNPCT/CN2012/076141 2012-05-28
CN2012076141 2012-05-28
US201261662629P 2012-06-21 2012-06-21
US61/662,629 2012-06-21

Publications (1)

Publication Number Publication Date
WO2013011061A1 true WO2013011061A1 (fr) 2013-01-24

Family

ID=46513780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/064108 WO2013011061A1 (fr) 2011-07-18 2012-07-18 Anticorps anti-oscar

Country Status (1)

Country Link
WO (1) WO2013011061A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506062A (ja) * 2013-12-16 2017-03-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 形質細胞様樹状細胞の枯渇

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US20020161201A1 (en) 1997-04-30 2002-10-31 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
WO2005040219A1 (fr) 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications
US20050238646A1 (en) 2001-01-17 2005-10-27 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2010040998A1 (fr) 2008-10-06 2010-04-15 Cambridge Enterprise Llimited Modulation de l'activité et de la différenciation de cellules exprimant le récepteur associé à l'ostéoclaste

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US20020161201A1 (en) 1997-04-30 2002-10-31 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20050238646A1 (en) 2001-01-17 2005-10-27 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (fr) 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications
WO2010040998A1 (fr) 2008-10-06 2010-04-15 Cambridge Enterprise Llimited Modulation de l'activité et de la différenciation de cellules exprimant le récepteur associé à l'ostéoclaste

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Immunology", 1992, GREENE PUBLISHING ASSOC. AND WILEY INTERSCIENCE
ANGAL ET AL., MOL IMMUNOL., vol. 30, pages 105 - 8
BIRD ET AL., SCIENCE, vol. 242, 1988
BOND ET AL., J. MOL. BIOL., vol. 332, 2003, pages 643 - 655
BRAND ET AL., EUR. J. IMMUNOL., vol. 28, 1998, pages 1673 - 1680
CAI; GAREN, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 6280 - 6285
CHOTHIA; LESK, J. MOL. BIOL, vol. 196, 1987, pages 901 - 917
DESMYTER ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 23645 - 23650
HARLOW ET AL.: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR
HOLLIGER; HUDSON, NAT BIOTECHNOL, vol. 2S, 2005, pages 1126 - 1136
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HUSTON ET AL., PNAS, vol. 85, 1988, pages 5879 - 5883
III ET AL., PROTEIN ENG, vol. 10, 1997, pages 949 - 57
JENG KC ET AL., IMMUNOL. LETT., vol. 45, no. 1-2, 1995, pages 13 - 17
MERCK ET AL., BLOOD, vol. 105, 2005, pages 3623 - 3632
MULLER, METH. ENZYMOL., vol. 92, 1983, pages 589 - 601
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506062A (ja) * 2013-12-16 2017-03-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 形質細胞様樹状細胞の枯渇

Similar Documents

Publication Publication Date Title
JP7610302B2 (ja) Ｃｃｒ８抗体及びその用途
EP3575318B1 (fr) Anticorps anti-pd-1 et son utilisation
CN110382536B (zh) 抗pd-1抗体及其用途
RU2756236C2 (ru) PD-L1 специфические антитела
JP6405242B2 (ja) Ｍｉｃａ結合剤
JP2021527441A (ja) Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用
WO2020177733A1 (fr) Protéine de fusion bifonctionnelle et son utilisation pharmaceutique
US20140056918A1 (en) Oscar antagonists
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN113248618B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
WO2013056984A1 (fr) Anticorps dirigés contre la chaîne alpha du récepteur d'il7 et leur utilisation pour préparer des candidats de médicament
WO2013011063A1 (fr) Anticorps anti-oscar
CN110678484B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
WO2021097800A1 (fr) Anticorps multispécifiques anti-pd-l1/anti-b7-h3 et leurs utilisations
JP2025041695A (ja) 抗体および使用方法
AU2013269652A1 (en) TLR3 binding agents
CA3148956A1 (fr) Anticorps monoclonal anti-cd47 et son utilisation
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
CN117043187A (zh) GARP/TGFβ1抗体及其应用
KR20220164473A (ko) 생체외 감마 델타 t 세포 집단
WO2013011062A2 (fr) Antagonistes oscar
EP4368640A1 (fr) Anticorps cd19 et son application
WO2023170434A1 (fr) Compositions et procédés pour moduler l'activité des macrophages
WO2018235964A1 (fr) Anticorps anti-tgf-bêeta1
WO2013011061A1 (fr) Anticorps anti-oscar

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12735311

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12735311

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载